Skip to main content

Table 1 Baseline characteristics of participants included in the study

From: Using the derived 28-joint disease activity score patient-reported components (DAS28-P) index as a discriminatory measure of response to disease-modifying anti-rheumatic drug therapy in early rheumatoid arthritis

Descriptor

Group 1

Group 2

Group 3

All

Classification

Responders

Partial responders

Non-responders

 

N (%)

58 (48%)

32 (26%)

31 (26%)

121

Age: mean (SD)

56 (16)

54 (15)

63 (11)

57 (15)

Females (%)

45 (78%)

25 (78%)

19 (61%)

89 (74%)

BMI: mean (SD)

26.4 (5.1)

27.4 (4.8)

30.6 (7.6)*

27.7 (6.0)

ACPA positive (%)

31/55 (56%)

14/31 (45%)

18/31 (58%)

63/117 (54%)

RF positive (%)

39/55 (71%)

13/31 (42%)

18/31(58%)

70/117 (60%)

Smoking (%)

 Never

29 (50%)

16 (50%)

7 (23%)

52 (43%)

 Former

20 (34%)

14 (44%)

15 (48%)

49 (41%)

 Current

9 (16%)

2 (6%)

9 (29%)

20 (17%)

 Odds ratioordinal (95% CI) for the likelihood of smoking

1.2 (0.5, 2.7)

1

3.6 (1.4, 9.2)*

 

Weeks polyarthritis: median (IQR)

16 (12, 24)

16 (12, 24)

20 (12, 28)*

16 (12, 24)

Randomized to fish oil (%)

38 (66%)

20 (63%)

17 (54%)

75 (62%)

  1. The odds ratio (highlighted in italics) was calculated for the likelihood of smoking
  2. *Significantly different from Group 2 (p < 0.05)
  3. SD standard deviation, BMI body mass index, ACPA anti-cyclic citrullinated peptide antibody, RF rheumatoid factor, CI confidence interval, IQR interquartile range